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Abstract
Background:  HIV disease itself is associated with increased healthcare utilization and healthcare
expenditures. HIV-infected persons with lipodystrophy have been shown to have poor self-perceptions of
health. We evaluated whether lipodystrophy in the HIV-infected population was associated with increased
utilization of healthcare services and increased healthcare costs.
Objective: To examine utilization of healthcare services and associated costs with respect to presence
of lipodystrophy among HIV-infected patients.
Methods: Healthcare utilization and cost of healthcare services were collected from computerized
accounting records for participants in a body image study among HIV-infected patients treated at a tertiary
care medical center. Lipodystrophy was assessed by physical examination, and effects of lipodystrophy
were assessed via body image surveys. Demographic and clinical characteristics were also ascertained.
Analysis of healthcare utilization and cost outcomes was performed via between-group analyses.
Multivariate modeling was used to determine predictors of healthcare utilization and associated costs.
Results: Of the 181 HIV-infected participants evaluated in the study, 92 (51%) had clinical evidence of
HIV-associated lipodystrophy according to physician examination. Total healthcare utilization, as measured
by the number of medical center visits over the study period, was notably increased among HIV-infected
subjects with lipodystrophy as compared to HIV-infected subjects without lipodystrophy. Similarly, total
healthcare expenditures over the study period were $1,718 more for HIV-infected subjects with
lipodystrophy than for HIV-infected subjects without lipodystrophy. Multivariate modeling demonstrated
strong associations between healthcare utilization and associated costs, and lipodystrophy score as
assessed by a clinician. Healthcare utilization and associated costs were not related to body image survey
scores among HIV-infected patients with lipodystrophy.
Conclusion:  Patients with HIV-associated lipodystrophy demonstrate an increased utilization of
healthcare services with associated increased healthcare costs as compared to HIV-infected patients
without lipodystrophy. The economic and healthcare service burdens of HIV-associated lipodystrophy are
significant and yet remain inadequately addressed by the medical community.
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Background
The HIV-associated lipodystrophy syndrome is character-
ized by alterations in body appearance related to changes
in body fat stores and has been described in up to 80% of
persons who have been exposed to antiretroviral therapies
[1-4]. These changes in body appearance have been
shown to result in body image dysphoria and reduced
body image-related quality of life among affected persons
[5,6]. In addition, HIV-infected persons with lipodystro-
phy have reported poorer physical health [7]. Among
other patient populations, poorer health perceptions [8]
and quality of life [9] have both been associated with
increased healthcare costs and utilization. However, little
is known about health services use among HIV-infected
patients with lipodystrophy.
Health services use is an important indicator of clinical
significance because it indicates patient suffering and
denotes social and economic burdens due to the explicit
and hidden (e.g. time lost from work) costs associated
with health services use. Health services use has been eval-
uated in the HIV-infected population, and HIV disease is
associated with elevated health services use [10]. How-
ever, the effect of lipodystrophy on health services use and
associated healthcare expenditures in this population has
yet to be explored. We therefore sought to determine
whether patients affected by HIV lipodystrophy exhibited
changes in their utilization of healthcare resources as
compared to HIV-infected patients without lipodystro-
phy. Our a priori hypothesis was that HIV-infected
patients with lipodystrophy would demonstrate increased
utilization of healthcare services with an associated
increase in healthcare expenditures as compared to HIV-
infected patients without lipodystrophy.
Results
Demographics
The demographic data of the one hundred and eighty-one
HIV-infected study participants are displayed in [see Addi-
tional file 1]. Patients with HIV-associated lipodystrophy
were older and demonstrated dyslipidemia and a history
of AIDS more frequently than patients without lipodystro-
phy. CD4 counts were higher (although not statistically
significant) and the interquartile range of HIV viral loads
was lower in subjects with lipodystrophy vs. subjects with-
out lipodystrophy.
Among the 92 patients with clinical evidence of HIV-asso-
ciated lipodystrophy, 15 (16%) had evidence of lipoatro-
phy only, 24 (26%) had evidence of lipohypertrophy
only, and 53 (58%) demonstrated a mixed lipoatrophy/
lipohypertrophy presentation. Patients with lipodystro-
phy reported physical changes for a duration of 28 (21,
48) [median(IQR)] months. Body image measures dem-
onstrated significantly increased body image dysphoria
and reduced body image-related quality of life among
HIV-infected patients with lipodystrophy as compared to
HIV-infected patients without lipodystrophy.
Healthcare Utilization and Lipodystrophy Status
Clinical lipodystrophy status was associated with health-
care utilization outcomes [see Additional file 2]. In partic-
ular, the total number of healthcare encounters was
significantly greater among patients with HIV-associated
lipodystrophy as compared to those without. Clinic visits
accounted for the majority of healthcare encounters, and
patients with HIV-associated lipodystrophy attended
more clinic visits than HIV-infected patients without lipo-
dystrophy. In addition, admission to the hospital was
more prevalent amongst patients with physician-defined
HIV-associated lipodystrophy as compared to those with-
out lipodystrophy, although associated length of stay and
healthcare costs did not differ according to lipodystrophy
status.
Healthcare expenditures paralleled healthcare use. Total
healthcare costs were significantly greater among patients
with HIV-associated lipodystrophy as compared to cate-
gory counterparts; patients with HIV-associated lipodys-
trophy spent $1,718 more than HIV-infected patients
without lipodystrophy during the year of observation.
Similarly, costs associated with clinic visits were greater
among patients with HIV-associated lipodystrophy than
non-lipodystrophy patients, although this did not reach
statistical significance.
Among patients with lipodystrophy, lipodystrophy sub-
categorizations (i.e. lipoatrophy only, lipohypertrophy
only, or mixed presentation) were not significantly associ-
ated with healthcare utilization outcomes (p > 0.05).
However, patients who reported a longer duration of lipo-
dystrophy changes demonstrated a significantly greater
number of healthcare encounters (23 (17, 33) vs. 13 (8,
25) visits, patients with lipodystrophy ≥ 28 months vs.
patients with lipodystrophy <28 months, p = 0.01) and
greater associated healthcare costs ($5,437 ($4,176,
$9,716) vs. $3,034 ($1,918, $5,751), patients with lipod-
ystrophy ≥ 28 months vs. patients with lipodystrophy <28
months, p = 0.01) compared to patients reporting lipod-
ystrophy changes for a shorter period.
Healthcare Utilization and AIDS and HCV Status
Healthcare utilization measures were also related to his-
torical AIDS status in the study cohort. The total number
of healthcare encounters was significantly greater among
patients with a history of AIDS as compared to those with-
out (17 (9, 26) vs. 12 (7, 20) visits, AIDS vs. non-AIDS, p
= 0.01). The majority of these encounters were accounted
for by scheduled clinic visits (17 (8, 25) vs. 11 (7, 20) vis-
its, AIDS vs. non-AIDS, p = 0.01). Admission rates to theAIDS Research and Therapy 2008, 5:14 http://www.aidsrestherapy.com/content/5/1/14
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hospital were similar between patients with and without
AIDS (p = 0.24).
Total healthcare expenditures were also greater among
HIV-infected patients with historical AIDS as compared to
patients without AIDS ($4,394 ($2,477, $8,138) vs.
$2,670 ($1,365, $4,959), AIDS vs. non-AIDS, p =
0.0008). Clinic costs were also greater among patients
with AIDS than non-AIDS patients ($3,014 ($1,424,
$4,672) vs. $2,148 ($847, $3,408), AIDS vs. non-AIDS, p
= 0.01). There were no differences in emergency room
related costs between groups categorized by history of
AIDS.
In contrast, presence of HCV did not affect healthcare uti-
lization outcomes (p = 0.70 and p = 0.76, healthcare
encounters and healthcare costs, respectively).
Healthcare Utilization and Cardiovascular Risk
Healthcare utilization outcomes were associated with car-
diovascular risk factors in the study cohort. Specifically,
the total number of healthcare encounters was signifi-
cantly greater among HIV-infected patients with hyperlip-
idemia and/or diabetes as compared to patient
counterparts (18 (9, 25) vs. 11 (7, 20) visits, HIV-infected
patients with hyperlipidemia and/or diabetes vs. HIV-
infected controls, p = 0.003). Total healthcare expendi-
tures were also greater among HIV-infected patients with
hyperlipidemia and/or diabetes as compared to category
comparisons ($4,373 ($2,266, $7,344) vs. $3,104
($1,493, $5,405), HIV-infected patients with hyperlipi-
demia and/or diabetes vs. HIV-infected controls, p =
0.07), although this did not reach statistical significance.
The total number of healthcare encounters (20 (11, 26)
vs. 11 (7, 20) visits, HIV-infected patients with hyperten-
sion vs. HIV-infected normotensive patients, p = 0.001)
and total healthcare expenditures ($4,764 ($2,719,
$8,925) vs. $2,773 ($1,656, $5,102), hypertensive vs.
normotensive HIV-infected patients, p = 0.002) were also
significantly greater among HIV-infected patients with
hypertension as compared to normotensive HIV-infected
patients.
Body Image measures and Healthcare Utilization 
outcomes in HIV-associated Lipodystrophy
Among patients affected by HIV-associated lipodystrophy,
body image measures did not correlate with number of
healthcare encounters (ρ = 0.09, p = 0.39 and ρ = -0.08, p
= 0.46, BIQLI and SIBID-S, respectively). Similarly, in this
subcohort, body image measures did not correlate with
healthcare expenditures (ρ = 0.09, p = 0.40 and ρ = -0.05,
p = 0.46, BIQLI and SIBID-S, respectively).
Multivariate modeling
In multivariate regression analysis, the relationship
between healthcare utilization (encounters) and lipodys-
trophy status (represented as lipodystrophy assessment
score) remained significant controlling for age, sex, HIV
viral load, CD4 count, and presence of cardiovascular risk
or HCV disease [see Additional file 3]. The relationship
between healthcare costs and lipodystrophy was also sig-
nificant in multivariate modeling [see Additional file 3].
Discussion
We performed an observational study among HIV-
infected patients in care to determine whether lipodystro-
phy status affects healthcare services utilization. Our find-
ings demonstrate that clinical somatic changes defined as
lipodystrophy are associated with increased healthcare
service utilization among HIV-infected patients despite
improved HIV disease status measures.
Prior studies of hospitalization and outpatient services
use among the HIV-infected community have demon-
strated a significant relationship between worsening dis-
ease status (as represented by decreasing CD4 count and
increasing HIV viral load) and increased health services
utilization [11]. In addition, data from the National
Ambulatory Medical Care Survey demonstrate that
patients co-infected with HIV and HCV demonstrated
increased hospitalization rates and hospital charges for
HCV liver complications over the period of 1994 to 2001
[12]. However, we demonstrate that lipodystrophy is also
a strong predictor of healthcare usage in analyses control-
ling for HIV disease status and HCV co-infection. Interest-
ingly, in our study cohort, HIV viral load and HCV co-
infection were not significantly related to healthcare utili-
zation outcomes, and patients with lipodystrophy dem-
onstrated higher CD4 counts and lower viral loads than
comparison counterparts. Lipodystrophy has been shown
to result from antiretroviral exposure and, in particular, is
relatively common among persons taking highly active
antiretroviral therapy (HAART) [2-4]. Although HAART
has reduced morbidity and increased the life expectancy
of persons infected with HIV [13,14], as reflected by
improved disease measures (such as increased CD4 count
and lower viral loads, as demonstrated by our cohort with
lipodystrophy), the expected decrease in healthcare usage
and healthcare expenditures has not been demonstrated
[11]. One potential reason for this lack of improvement in
healthcare utilization outcomes may be the notable prev-
alence of lipodystrophy in the HAART-exposed HIV-
infected population (up to 80% in some studied popula-
tions [4]) and associated increases in healthcare usage by
persons affected by HIV-associated lipodystrophy as dem-
onstrated in our cohort.AIDS Research and Therapy 2008, 5:14 http://www.aidsrestherapy.com/content/5/1/14
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The healthcare costs associated with lipodystrophy in our
cohort was significant, even over the relatively short-time
period of 1 year. The financial burden of HIV-associated
lipodystrophy is substantial. The management of lipodys-
trophy remains a major challenge in HIV clinical care,
given the lack of a currently available cure. Some therapies
do hold promise; however, the cost of such therapies are
often quite prohibitive for disadvantaged consumers [15].
Cosmetic options are available, but are not reimbursed by
health insurers and thus must be paid out-of-pocket by
often underprivileged consumers. In addition, clinical
lipodystrophy is not only a cosmetic problem but also has
been shown to co-exist with metabolic (glucose intoler-
ance and hyperlipidemia [16]) and clinical (hypertension
[17,18]) derangements associated with development of
diabetes and cardiovascular disease, which incur signifi-
cant healthcare costs [19-22]. In our cohort, patients with
diabetes, dyslipidemia, and/or hypertension were found
to have increased healthcare utilization and incur greater
associated healthcare costs; however, the associations
between diabetes and dyslipidemia (frequent cardiovas-
cular risk factors associated with lipodystrophy) and
healthcare outcomes did not remain significant after con-
trolling for severity of lipodystrophy in multivariate anal-
ysis. Among non-HIV infected populations, visceral fat
accumulation is associated with metabolic abnormalities
and increased cardiovascular risk [23,24]. However, in our
study, we did not demonstrate increased healthcare utili-
zation among HIV-infected patients with lipohypertro-
phy-predominant lipodystrophy as compared to other
lipodystrophy subtypes. Rather, we demonstrate
increased healthcare use and cost among patients with
any clinical HIV-associated lipodystrophy (inclusive of
lipoatrophy and lipohypertrophy) as compared to HIV-
infected patients without lipodystrophy. Healthcare utili-
zation evaluation according to presence or absence of
lipodystrophy is appropriate given that the data regarding
visceral fat accumulation and metabolic abnormalities in
the HIV-infected population is not as compelling as in
non-HIV infected populations, and lipoatrophy also has
been associated with metabolic and cardiovascular conse-
quences [25].
Dramatic alterations in body appearances, such as is seen
in HIV lipodystrophy, can distort the function and experi-
ence of the human body. Previously, we and others dem-
onstrated that HIV lipodystrophy has significant negative
effects on psychosocial well-being and quality of life [5,6].
In other populations with body cosmetic alterations, such
as obese persons [26], psychological distress can lead to
impairment of physical well-being and increased health-
care utilization. Although we demonstrate increased
healthcare utilization and healthcare expenditures among
patients affected by the HIV lipodystrophy syndrome as
compared to HIV-infected patients without lipodystro-
phy, we did not demonstrate a direct association between
healthcare utilization or costs and measures of body
image dysphoria or body image-related quality of life.
Our findings are subject to a number of limitations. First,
subjects recruited for the study were participants in a body
image study and participants may have self-selected to
participate in the study owing to their increased anxiety
regarding body image. However, both patients with and
without lipodystrophy were invited to participate in the
study. Second, we retrieved healthcare utilization and cost
data from one medical entity. However, this particular
medical entity was the primary coordinating center for the
HIV care for all study participants and therefore it is likely
that participants did not seek care at other local medical
offices. Nevertheless, we were not able to collect or
account for any out-of-system charges. In this particular
study, we chose to limit cost retrieval to one year only in
order to reflect costs associated with the physical findings
of lipodystrophy as determined by physician examina-
tion. Additional study will be needed to determine the
longitudinal effects of lipodystrophy on healthcare utili-
zation after initial diagnosis as compared to healthcare
utilization previous to development of lipodystrophic
body changes. Third, lipodystrophy was only assessed at a
single time point; therefore, changes in body lipodystro-
phy on healthcare utilization over time could not be
determined. Prior data has shown that lipodystrophy
changes stabilize 18 to 24 months following initial devel-
opment [27]. About half of subjects with lipodystrophy in
this cohort had reported lipodystrophy of at least 28
months duration at the time of study, and subjects with a
longer duration of lipodystrophy demonstrated greater
healthcare utilization compared to those with a shorter
duration of lipodystrophy. Thus, it would appear that our
assessment may have actually underestimated the health-
care utilization of lipodystrophy subjects by including
patients who had "early" lipodystrophy; the economic
and healthcare service burdens associated with lipodystro-
phy may therefore be even greater than we have presented.
Lastly, our findings of a significant relationship between
HIV-associated lipodystrophy and healthcare utilization
are correlative and not necessarily causal. We did attempt
to control for potential confounders by including clinical
and demographic variables in our analyses. Nevertheless,
entered variables in our multivariate modeling of health-
care outcomes explained only a portion of the observed
variability; therefore, lipodystrophy status accounts for
but a portion of healthcare utilization and costs in our
cohort. Alternatively, it is possible that unmeasured con-
founders explain the demonstrated relationship.
Conclusion
In summary, we explored and provide evidence of the
clinical and economic burden of HIV-associated lipodys-AIDS Research and Therapy 2008, 5:14 http://www.aidsrestherapy.com/content/5/1/14
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trophy on healthcare utilization. Our study documents
the association between healthcare use and severity of
lipodystrophy using individual-level data, while taking
age, sex, cardiovascular risk, HCV and AIDS status into
consideration. Additional study is needed to further estab-
lish the clinical resource and financial burdens of lipodys-
trophy using data from a longer period.
Methods
Participants and Setting
181 HIV-infected subjects were recruited from an aca-
demic, multidisciplinary adult HIV clinic in San Diego for
a study evaluating body image. Participants completed
body image surveys and were assessed by a physician for
the presence or absence of lipodystrophy. Details and
main study outcomes of the body image study have been
previously published [5,6] and are described below.
Healthcare utilization outcomes
Healthcare utilization outcomes extracted from the medi-
cal record for each subject included number of ambula-
tory care (scheduled and urgent) visits, emergency room
visits, hospitalizations and length of stay incurred over a
12-month period (10 months prior and 2 months after
the study visit date) proximal to the assessment of lipod-
ystrophy. In this study, our financial outcome for health-
care utilization was healthcare costs. Activity based
costing was used to determine costs associated with
patient care and included both direct (including labora-
tory testing, radiologic examinations, pharmacy, blood
usage, respiratory care, nursing care, operating room and
clinic room expenses, etc.) and indirect costs (overhead
costs of plant maintenance, administration, medical
records, human resources and information services). We
chose to not evaluate healthcare charges, since charges
often are subject to institutional marketing strategies and
markup or markdown policy, and may vary by payor
[28,29].
Lipodystrophy assessment
A physical examination was performed by two study phy-
sicians to determine presence or absence of lipodystro-
phy. In their determination of the presence of
lipodystrophy, study physicians were asked to assess 7
specific body areas for changes in fat distribution: face,
neck and shoulder, arms, abdomen, buttocks and legs,
and breasts using a 0-to-2 point bi-directional scale with
1/2-point increments to determine severity; the lipodys-
trophy assessment score was then determined by totaling
the subscores of body changes from these 7 areas. While
scale scores for each body area was noted in the positive
(lipohypertrophy) or negative (lipoatrophy) direction,
the lipodystrophy assessement score was calculated via
addition of absolute value scores in each area. Thus, a
higher lipodystrophy assessment score indicated a greater
severity of lipodystrophy (inclusive of both lipohypertro-
phy and lipoatrophy) and ranged from 0 to 14. Between
the two study physicians, agreement regarding absence or
presence of lipodystrophy was 91% (both assessed 11 ran-
domly selected subjects)[5].
Questionnaires
The Body Image Quality of Life Inventory (BIQLI) is a
clinical assessment of how an individual's body image
impacts his or her life. The BIQLI uses a 7-point response
format ranging from very negative (-3) to very positive
(+3) effects of body image on 19 life domains [30]. The
nineteen-item BIQLI is internally consistent and has been
demonstrated to converge significantly with multiple
measures of body-image evaluation as well as with body
mass. The BIQLI is valuable for quantifying how persons'
body image experiences affect a broad range of life
domains, including sense of self, social functioning, sexu-
ality, emotional well-being, eating, exercise, grooming,
etc. The BIQLI is scored as an average numeric score of the
19 items where a more negative score reflects a more neg-
ative body image.
The Situational Inventory of Body-Image Dysphoria
(SIBID) is an assessment of the frequency of negative
body-image emotions across specific situational contexts.
This inventory asks respondents how often they experi-
ence body-image dysphoria or distress (according to a
numeric range of 0 (never) to 4 (always)) in each of 48
identified situations-including both social and nonsocial
contexts and activities related to exercising, grooming, eat-
ing, intimacy, physical self-focus, and appearance altera-
tions. Research has confirmed that this is an internally
consistent, stable, and convergently valid measure of
body-image affect that is responsive to body-image ther-
apy. Recently, a 20-item short form of the SIBID has been
validated and found to correlate highly (r > .95) with the
original longer version [31]. The short form of the SIBID
(SIBID-S) was used in this study. The SIBID-S is scored as
the numeric mean score of its 20 items where a higher
score is associated with increased body image dysphoria.
Other data
Demographic data were also collected. CD4 count, HIV
viral load, and duration of lipodystrophy changes at the
time of the lipodystrophy evaluation were extracted from
the medical record. Diagnoses of hypertension, dyslipi-
demia, diabetes, and HCV were extracted from the medi-
cal record via associated ICD-9 codes and/or laboratory
results.
Response Coding
Healthcare utilization outcomes, body image question-
naire scores, age, CD4 count and HIV viral load were not
modified. Racial response categories included: white,AIDS Research and Therapy 2008, 5:14 http://www.aidsrestherapy.com/content/5/1/14
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black, Hispanic, Asian, or other; for the purposes of anal-
ysis, these groups were collapsed according to Caucasian
or non-Caucasian origin. Sex was coded as male or female.
Lipodystrophy status was coded as present or absent.
Among patients with lipodystrophy, further categoriza-
tion of lipodystrophy according to lipodystrophy assess-
ment scores was performed into lipoatrophy only,
lipohypertrophy only, and mixed lipoatrophy/lipohyper-
trophy groups. Patients with lipodystrophy were also cat-
egorized according to duration of lipodystrophy changes
(<28 months vs. ≥ 28 months). HIV disease status was
coded as having ever met AIDS diagnostic criteria or not
(i.e. history of AIDS or not). Diagnoses of hypertension,
dyslipidemia, diabetes, and HCV were coded as present or
not.
Statistical Analysis
Healthcare utilization outcomes and other selected meas-
ures were compared according to presence or absence of
lipodystrophy, lipodystrophy subcategories (among
patients with HIV-associated lipodystrophy only), history
of AIDS, and history of cardiovascular risk or HCV using
chi-square statistics for categorical variables and the Wil-
coxon rank sum test for continuous variables. Spearman's
correlation analysis was used to determine potential asso-
ciations between body image measures and healthcare
utilization outcomes among the subpopulation affected
by HIV-associated lipodystrophy. Multivariate linear
regression analyses were then applied to identify predic-
tors of healthcare utilization outcomes after adjusting for
clinical variables (age, sex, HIV viral load, CD4 count, and
presence of cardiovascular risk or HCV). Clinical variables
entered into the regression models were selected owing to
their known associations with lipodystrophy, HIV disease,
and/or healthcare outcomes. For multivariate regression
methods and for correlation analyses, we transformed
some variables to improve the symmetry of their distribu-
tions. For example, log10 transformation improved the
symmetry of CD4 count and HIV viral load distributions.
Statistical analyses were performed using JMP 5.0 (SAS
Institute, Inc., Cary, NC).
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